Edgar Filing: HALOZYME THERAPEUTICS INC - Form 4

HALOZYME THERAPEUT Form 4 April 15, 2015	ICS INC				
				-	PPROVAL
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549					3235-0287
Check this box if no longer subject to Section 16.	MENT OF CHA	NGES IN BENEFICIAL OV SECURITIES	WNERSHIP OF	Expires: Estimated burden hou	
abligations	(a) of the Public U	16(a) of the Securities Exchar Jtility Holding Company Act nvestment Company Act of 1	of 1935 or Section	response	
(Print or Type Responses)					
1. Name and Address of Reporting LEONHARDT HARRY J	Symbol	er Name and Ticker or Trading ZYME THERAPEUTICS IALO]	5. Relationship of Issuer (Chec	Reporting Per	
(Last) (First) (C/O HALOZYME THERAPEUTICS, INC., 11 SORRENTO VALLEY BLV	(Month/ 04/13/ 388	of Earliest Transaction Day/Year) 2015	Director X Officer (give below) SVP		% Owner her (specify
(Street)		Filed(Month/Day/Year) Appl _X_		l or Joint/Group Filing(Check ine) ed by One Reporting Person ed by More than One Reporting	
SAN DIEGO, CA 92121			Person		eporting
(City) (State)	(Zip) Tal	ble I - Non-Derivative Securities A	cquired, Disposed of	f, or Beneficia	lly Owned
1.Title of Security (Instr. 3)2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. 4. Securities TransactionAcquired (A) or Code Disposed of (D) (Instr. 8) (Instr. 3, 4 and 5) (A) or	SecuritiesFBeneficially(1)Owned(1)	5. Ownership Form: Direct D) or Indirect I) Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Reminder: Report on a separate line	e for each class of sec	Code V Amount (D) Price			

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amou Underlying Securi (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amo Num Shar
Options to purchase common stock	\$ 15.63	04/13/2015		А	225,000	04/13/2016 <u>(1)</u>	04/13/2025	Common Stock	225
Restricted Stock Units	\$ 0	04/13/2015		А	27,500	04/13/2016(2)	04/13/2025	Common Stock	27

Edgar Filing: HALOZYME THERAPEUTICS INC - Form 4

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
LEONHARDT HARRY J C/O HALOZYME THERAPEUTICS, INC. 11388 SORRENTO VALLEY BLVD. SAN DIEGO, CA 92121			SVP, GC and CCO	

Signatures

/s/ Harry J. Leonhardt 04/15/2015

<u>**</u>Signature of Reporting Person

eporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This option vests one-fourth on such date and 1/48 monthly thereafter.
- (2) This award vests one-fourth on such date and one-fourth on each anniversary thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.